Notch1 functions as a tumor suppressor in mouse skin

Michaël Nicolas, Anita Wolfer, Kenneth Raj, +7

Nature Genetics

MedicineTumor SuppressorDermatologyCancer BiologyCell Biology +3

Inactivation of Notch1 Impairs VDJβ Rearrangement and Allows pre-TCR-Independent Survival of Early αβ Lineage Thymocytes

Anita Wolfer, Anne Wilson, Mohamed Nemir, +2

Immunity

Signal TransductionCell RegulationLymphocyte DevelopmentImmune RegulationImmunology +5

Inactivation of Notch1 in immature thymocytes does not perturb CD4 or CD8 T cell development

Anita Wolfer, Talitha R. Bakker, Anne Wilson, +7

Nature Immunology

Immature ThymocytesDevelopmental BiologyLymphocyte DevelopmentImmune Cell DevelopmentImmunology +6

Asymmetric cancer cell division regulated by AKT

Ipsita Dey‐Guha, Anita Wolfer, Albert C. Yeh, +6

Proceedings of the National Academy of Sciences

MYC regulation of a “poor-prognosis” metastatic cancer cell state

Anita Wolfer, Ben S. Wittner, Daniel Irimia, +14

Proceedings of the National Academy of Sciences

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated ( gBRCA m) platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Yvette Drew, Maja J.A. de Jonge, Sook Hee Hong, +14

Gynecologic Oncology

Gbrca MMedicineGynecologyPathologyCancer Treatment +4

Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy

Xavier Pivot, F. Marmé, Rebecca Koenigsberg, +3

Annals of Oncology

Feasibility and Safety of Pressurized Intraperitoneal Aerosol Chemotherapy for Peritoneal Carcinomatosis: A Retrospective Cohort Study

Martin Hübner, Hugo Teixeira Farinha, Fabian Grass, +4

Gastroenterology Research and Practice

Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers

Sana Intidhar Labidi‐Galy, Thibault De La Motte Rouge, Olfa Derbel, +21

Gynecologic Oncology

Ovarian CancersMedicineCancer ManagementProlonged ResponseGynecology +7

A phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC)

Roisin E. O’Cearbhaill, Anita Wolfer, Paul DiSilvestro, +16

Annals of Oncology